Krystal Biotech (KRYS) Gross Margin (2023 - 2026)
Krystal Biotech (KRYS) posted quarterly Gross Margin of 94.6% for Q2 2026, up 206.0% year-over-year from 30.92% in Q2 2025, and little changed on a QoQ basis from 94.57% in Q1 2026.
Powered by 
Analysis
Krystal Biotech (KRYS) Gross Margin (2023 - 2026) Analysis & Trends
Krystal Biotech has reported Gross Margin for 4 years, with the latest figure at 94.6% in Q2 2026.
- Gross Margin for Q2 2026 came in at 94.6%, up 206.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 94.64% (up 127.0% YoY), and the FY2025 annual result was 94.08%, up 98.0% from the prior year.
- Gross Margin steadied at 94.6% in Q2 2026, from 94.57% in the prior quarter.
- Over five years, Gross Margin peaked at 97.39% in Q3 2023 and troughed at 91.45% in Q2 2024.
- A 4-year average of 94.07% and a median of 94.43% in 2026 frame the typical range for Gross Margin.
- The widest annual swing landed in 2024, when Gross Margin slumped 537 bps; it then surged 361 bps in 2025.
- A 4-year view of Gross Margin shows it stood at 93.19% in 2023, then climbed by 1 bps to 94.57% in 2024, then declined by 1 bps to 93.85% in 2025, then rose by 1 bps to 94.6% in 2026.
- Per Business Quant data, the three most recent Gross Margin figures were 94.6% in Q2 2026, 94.57% in Q1 2026, and 93.85% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Krystal Biotech | 10.61 Bn | 9.76 Bn | 112.79 Mn | 94.60% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 94.60% |
| Mar 31, 2026 | 94.57% |
| Dec 31, 2025 | 93.85% |
| Sep 30, 2025 | 95.64% |
| Jun 30, 2025 | 92.54% |
| Mar 31, 2025 | 94.30% |
| Dec 31, 2024 | 94.57% |
| Sep 30, 2024 | 92.03% |
| Jun 30, 2024 | 91.45% |
| Mar 31, 2024 | 94.66% |
| Dec 31, 2023 | 93.19% |
| Sep 30, 2023 | 97.39% |